"...simply walk away from hundreds of millions of dollars..." Well, if it's a choice between walking away from money poorly invested and continuing to flush money down into bottomless well of losses, which would you choose?
Not to mention, even if SNY cancels the deal, MNKD will still owe them whatever the current balance on the 175 million dollar loan. So SNY recoups at least some of their loss.
No, studies funded by MNKD or SNY don't count. I'm not really trying to argue any point. I'm trying to understand Schimmer's rather radical change in attitude. Before, he blamed things on spirometry and on, based on a survey, endos not knowing about afrezza. Now he doesn't mention spirometry, apparently is satisfied that docs know about afrezza, surveys only five of them and flushes MNKD down the toilet. His final conclusion is that docs aren't interested in using it. In other words, spirometry is a non-issue now simply because docs aren't going to be prescribing afrezza. I wonder if he's thinking along Feurstein's line -- that SNY will dump afrezza at the first opportunity.
"once they've decided to prescribe Afrezza,"??? Well, you see, that's just it. My impression, like Schimmer's, is that endos simply don't like the drug and don't plan on using it. Hence, SNY is putting no more effort into marketing spirometers to endos simply because there is no reason to. Have you seen any really favorable articles written by endos?
"Reportedly, primary care physicians typically..."? Really? What percentage? Can you support your assertion with real statisitcs?
"There may be other actions too..."? Really? The sun "may" rise in the west tomorrow, but I'd just as soon not bet on it. That was my original question -- what EXACTLY has SNY done to solve the alleged spirometry problem?
Has it crossed anyone's mind that perhaps spirometry never really was a problem? That the endos simply didn't like afrezza and weren't planning on using it anyway? I noticed that Stillman didn't bring up the spirometry issue in his "survey," whereas before he said -- as I recall -- that it was a "primary" issue. It seems odd that he would so casually dismiss it now.
The link takes you to nothing more than a product information page, ditto for the link on the afrezzapro page. And THAT is ALL they're doing? It looks more like nothing more than old fashioned "bait and switch" to me -- using afrezza to promote their own spirometers than doing anything to boost spirometry use in docs' offices.
Thanks for the reply but it really doesn't address the central issue of what Sanofi actually did to resolve the issue. What exactly did they do? No one seems to know. I sure can't find that they have done anything.
Seems like a few months ago, it was a major issue, and then MNKD said SNY had done "something" about it, but didn't say -- typical for MNKD - what! Has SNY simply given up marketing to endos? I really don't see what SNY could do to overcome the problem otherwise.